Share Consolidation
2009年10月8日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMCRYO
RNS Number : 4183A
Cryo-Save Group NV
08 October 2009
8 October 2009
Cryo-Save Group NV
Share Consolidation
Cryo-Save Group N.V. (AIM: CRYO, "Cryo-Save" or "the Company"), Europe's leading
stem cell bank, confirms that pursuant to the passing of the relevant
resolutions at an EGM of the Company held on 5 October 2009, and as notified on
that day, the proposed 5:1 share consolidation has this morning become
effective.
As result of the share consolidation the Company's authorised share capital now
comprises 9,639,191 ordinary shares of EUR0.10 each; the associated depository
interests for these ordinary shares will commence trading at 8:00am today under
ISIN NL0009272137.
+------------------------------------+---------------------------------+
| For further details: | |
+------------------------------------+---------------------------------+
| | |
+------------------------------------+---------------------------------+
| Cryo-Save Group | + 31 (0)575 548998 |
+------------------------------------+---------------------------------+
| Marc Waeterschoot, Chief Executive | |
| | |
+------------------------------------+---------------------------------+
| Arnoud van Tulder, Chief Financial | |
| Officer | |
+------------------------------------+---------------------------------+
| | |
+------------------------------------+---------------------------------+
| Daniel Stewart & Company plc | + 44 (0) 20 7776 6550 |
+------------------------------------+---------------------------------+
| Simon Leathers | |
+------------------------------------+---------------------------------+
| | |
+------------------------------------+---------------------------------+
| College Hill | + 44 (0) 20 7457 2020 |
+------------------------------------+---------------------------------+
| Adrian Duffield/Rozi Morris | |
+------------------------------------+---------------------------------+
About Cryo-Save
With more than 115,000 samples saved, Cryo-Save is the leading stem cell bank in
Europe and one of the fastest growing in the world. Driven by its international
business strategy, Cryo-Save is now represented in 38 countries on three
continents and has state-of-the-art processing facilities in Belgium, Germany,
Dubai, India and France (under construction).
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to
make an important contribution to conquer possible life-threatening diseases in
the future. As a service to the public, Cryo-Save offers a Cost-free Family
Donation Programme, free of charge, to families wishing to store their newborn's
umbilical cord blood stem cells for a family member diagnosed with a
life-threatening disease treatable by stem cells. The company is committed to
further improve stem cell cryopreservation techniques, by participating in
European Commission funded projects, in Universities and Hospitals.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CARZGMGGKNKGLZM
Cryo-Save (LSE:CRYO)
過去 株価チャート
から 5 2024 まで 6 2024
Cryo-Save (LSE:CRYO)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Cryo-Save (ロンドン証券取引所): 0 recent articles
その他のCryo-Saveニュース記事